Alan M. Garber's Insider Trades & SAST Disclosures
Alan M. Garber's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 1,199 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Alan M. Garber.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals, Inc. | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 1,199 | 1,199 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 398 | 6,872 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 3,142 | 3,142 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Alan M. Garber | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2024 | 23,491 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Alan M. Garber | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.57 per share. | 21 Mar 2024 | 23,491 | 54,908 (0%) | 0% | 19.6 | 459,719 | Common Stock |
| Exelixis Inc | Alan M. Garber | Director | Sale of securities on an exchange or to another person at price $ 24.01 per share. | 21 Mar 2024 | 19,205 | 35,703 (0%) | 0% | 24.0 | 461,112 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 1,741 | 1,741 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 584 | 6,474 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Alan M. Garber | Director | Sale of securities on an exchange or to another person at price $ 17.49 per share. | 21 Feb 2023 | 40,000 | 31,417 (0%) | 0% | 17.5 | 699,600 | Common Stock |
| Exelixis Inc | Alan M. Garber | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Alan M. Garber | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.30 per share. | 21 Feb 2023 | 40,000 | 71,417 (0%) | 0% | 6.3 | 252,000 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2022 | 4,462 | 4,462 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Alan M. Garber | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Alan M. Garber | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.13 per share. | 01 Mar 2022 | 40,000 | 52,718 (0%) | 0% | 3.1 | 125,200 | Common Stock |
| Exelixis Inc | Alan M. Garber | Director | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 01 Mar 2022 | 21,301 | 31,417 (0%) | 0% | 21 | 447,321 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2021 | 6,067 | 6,067 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Alan M. Garber | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Alan M. Garber | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 15 Mar 2021 | 40,000 | 52,718 (0%) | 0% | 3.4 | 135,200 | Common Stock |
| Exelixis Inc | Alan M. Garber | Director | Sale of securities on an exchange or to another person at price $ 23.60 per share. | 15 Mar 2021 | 40,000 | 12,718 (0%) | 0% | 23.6 | 944,000 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 2,264 | 2,264 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharmaceuticals, Inc. | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 699 | 5,890 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Alan M. Garber | Director | Sale of securities on an exchange or to another person at price $ 24.42 per share. | 21 May 2020 | 36,111 | 12,718 (0%) | 0% | 24.4 | 881,831 | Common Stock |
| Exelixis Inc | Alan M. Garber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2020 | 30,750 | 30,750 | - | - | Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges